The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

  • Biochem Biophys Res Commun. 2021 Nov 12;578:91-96. doi: 10.1016/j.bbrc.2021.09.023.
Dong-Kyun Ryu  1 ,  Bobin Kang  1 ,  Hanmi Noh  1 ,  Sun-Je Woo  2 ,  Min-Ho Lee  3 ,  Patricia M Nuijten  4 ,  Jong-In Kim  1 ,  Ji-Min Seo  1 ,  Cheolmin Kim  1 ,  Minsoo Kim  1 ,  Eunji Yang  2 ,  Gippeum Lim  2 ,  Seong-Gyu Kim  2 ,  Su-Kyeong Eo  2 ,  Jung-Ah Choi  2 ,  Manki Song  2 ,  Sang-Seok Oh  3 ,  Hyo-Young Chung  3 ,  Aloys Sl Tijsma  4 ,  Carel A van Baalen  4 ,  Ki-Sung Kwon  1 ,  Soo-Young Lee  5
Affiliations
  • 1. Biotechnology Research Institute, Celltrion Inc., Incheon, South Korea.
  • 2. Science Unit, International Vaccine Institute, Seoul, South Korea.
  • 3. New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, South Korea.
  • 4. Viroclinics Biosciences, Rotterdam, the Netherlands.
  • 5. Biotechnology Research Institute, Celltrion Inc., Incheon, South Korea. Electronic address: [email protected].
PMID: 34547629 DOI: 10.1016/j.bbrc.2021.09.023
Abstract

The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the Antiviral effect of CT-P59 on Gamma, Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal studies. CT-P59 showed neutralization against Gamma, Delta, Epsilon, and Kappa variants in cells, with reduced susceptibility. The mouse challenge experiments with Gamma and Delta variants substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against Gamma and Delta variants Infection, hinting that CT-P59 has therapeutic potential for patients infected with Gamma, Delta and its associated variants.

Keywords
CT-P59; Delta; Gamma; Regdanvimab; SARS-CoV-2 variant; Therapeutic antibody.
Products